Gapping down
In reaction to disappointing earnings/guidance: SWI -11.9%, CYT -9%, ANGO -3.3%, EDGW -2%
Other news: DSCO -17.8% (announces an underwritten public offering of units; size not disclosed), NRX -17.5% (prices $7.5 mln public offering of 1.5 mln shares of common stock and warrants at $5 per share and accompanying warrant), TROV -8.7% (to sell shares of its common stock), RDHL -6.5% (prices its upsized offering of 2.462 mln ADSs at $16.25/share), NBG -2.7% (cont vol surrounding Greek banking system), FIT -1.7% (cont vol post IPO), ESV -1.6% ( ConocoPhillips (COP) confirms a notice of termination for the three-year ENSCO DS-9 drillship contract -- ESV does not anticipate a material negative impact to its financial results for 2015 and 2016), XOMA -1.5% ( confirms its gevokizumab development partner, Servier, remains on track to report top-line pivotal Phase 3 EYEGUARD-B data the week of July 20, 2015), XRX -1.2% (announces changes in its Government Healthcare Solutions strategy resulting from review of future market opportunities; will record an impairment charge of $0.08/share), WPX -0.9% (prices its upsized offering of 30 mln shares of its common stock at $10.10/share), GEL -0.5% (prices its offering of 9 mln common units representing limited partner interests at $43.77/share)
Analyst comments: BBY -4.5% (downgraded to Underperform from Buy at BofA/Merrill), CS -2.2% (downgraded to Hold from Buy at Deutsche Bank), STAG -2.1% (downgraded to Sell from Neutral at UBS), NOV -1.7% (downgraded to Sell from Neutral at UBS)
In reaction to disappointing earnings/guidance: SWI -11.9%, CYT -9%, ANGO -3.3%, EDGW -2%
Other news: DSCO -17.8% (announces an underwritten public offering of units; size not disclosed), NRX -17.5% (prices $7.5 mln public offering of 1.5 mln shares of common stock and warrants at $5 per share and accompanying warrant), TROV -8.7% (to sell shares of its common stock), RDHL -6.5% (prices its upsized offering of 2.462 mln ADSs at $16.25/share), NBG -2.7% (cont vol surrounding Greek banking system), FIT -1.7% (cont vol post IPO), ESV -1.6% ( ConocoPhillips (COP) confirms a notice of termination for the three-year ENSCO DS-9 drillship contract -- ESV does not anticipate a material negative impact to its financial results for 2015 and 2016), XOMA -1.5% ( confirms its gevokizumab development partner, Servier, remains on track to report top-line pivotal Phase 3 EYEGUARD-B data the week of July 20, 2015), XRX -1.2% (announces changes in its Government Healthcare Solutions strategy resulting from review of future market opportunities; will record an impairment charge of $0.08/share), WPX -0.9% (prices its upsized offering of 30 mln shares of its common stock at $10.10/share), GEL -0.5% (prices its offering of 9 mln common units representing limited partner interests at $43.77/share)
Analyst comments: BBY -4.5% (downgraded to Underperform from Buy at BofA/Merrill), CS -2.2% (downgraded to Hold from Buy at Deutsche Bank), STAG -2.1% (downgraded to Sell from Neutral at UBS), NOV -1.7% (downgraded to Sell from Neutral at UBS)